Is Surrozen, Inc./DE (SRZN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.7% / 30% | 14.9% / 30% | 1.1% / 30% | 15.89% / 5% | ✗ NOT HALAL |
| DJIM | 3.7% / 33% | 14.9% / 33% | 1.1% / 33% | 15.89% / 5% | ✗ NOT HALAL |
| MSCI | 17.5% / 33% | 71.3% / 33% | 5.2% / 33% | 15.89% / 5% | ✗ NOT HALAL |
| S&P | 3.7% / 33% | 14.9% / 33% | 1.1% / 33% | 15.89% / 5% | ✗ NOT HALAL |
| FTSE | 17.5% / 33% | 71.3% / 33% | 5.2% / 50% | 15.89% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2393.8% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -35.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$18M |
| Total Debt | $8M |
| Current Ratio | 9.2 |
| Total Assets | $48M |
Price & Trading
| Last Close | $28.00 |
| 50-Day MA | $24.58 |
| 200-Day MA | $16.16 |
| Avg Volume | 104K |
| Beta | 0.6 |
|
52-Week Range
$5.90
| |
About Surrozen, Inc./DE (SRZN)
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Surrozen, Inc./DE (SRZN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Surrozen, Inc./DE is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Surrozen, Inc./DE's debt ratio?
Surrozen, Inc./DE's debt ratio is 3.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 17.5%.
What are Surrozen, Inc./DE's key financial metrics?
Surrozen, Inc./DE has a market capitalization of $332M, and revenue of $11M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.